Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

NCT05170438 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT05170438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05170438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
June 30, 2028
Enrollment
51 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer